ArticleJournal of neuro-oncology2021
Article in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06466031 (Application of FET-PET in Fusion With MRI in the Surgical Treatment and Postoperative Radiotherapy of Glioblastoma Multiforme - a Randomized, Blinded, Prospective Study), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Application of FET-PET in Fusion With MRI in the Surgical Treatment and Postoperative Radiotherapy of Glioblastoma Multiforme - a Randomized, Blinded, Prospective Study
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- Imaging strategies for delineating glioma margins: Aiming at precise therapy.Fundamental research · 2026Review
- Reconstruction matters: influence of EARL standards and BSREM in [EJNMMI research · 2026Article
- Characteristics of [European journal of nuclear medicine and molecular imaging · 2026Article
- [Journal of neuro-oncology · 2026Article
- A New Fluorine-18-Fluoroethyltyrosine Positron-Emission-Tomography/Magnetic-Resonance-Based Tumor Resection Plan Improved the Prognosis of Glioblastoma Patients. A Multicenter Validated Study.Research (Washington, D.C.) · 2026Article
- Extent of reoperation predicts survival in recurrent IDH-wildtype glioblastoma based on institutional data and individual patient data meta analysis.Discover oncology · 2025Article
- Improving the Response of High-Grade Glioma (HGG) Cells to Temozolomide Treatment Through Combination With Imatinib.Cureus · 2025Article
- Article
- Precision Surgery for Glioblastomas.Journal of personalized medicine · 2025Review
- Contribution of [Pharmaceuticals (Basel, Switzerland) · 2024Review
- A Biopsy-Controlled Prospective Study of Contrast-Enhancing Diffuse Glioma Infiltration Based on FET-PET and FLAIR.Cancers · 2024Article
- Exploring the association of glioma tumor residuals from incongruent [European journal of nuclear medicine and molecular imaging · 2024Article
- Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma.Nature communications · 2023Article
- Recapitulating the Key Advances in the Diagnosis and Prognosis of High-Grade Gliomas: Second Half of 2021 Update.International journal of molecular sciences · 2023Review
- Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know.AJNR. American journal of neuroradiology · 2023Review
- Therapy Defining at Initial Diagnosis of Primary Brain Tumor-The Role ofBiomedicines · 2023Article
- A Systematic Review of Amino Acid PET Imaging in Adult-Type High-Grade Glioma Surgery: A Neurosurgeon's Perspective.Cancers · 2022Review
- Refining Glioblastoma Surgery through the Use of Intra-Operative Fluorescence Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Multi-threshold volumetricNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePET using radiolabeled amino acid [
methodsWe retrospectively analyzed imaging and survival data from patients with primary and recurrent WHO grade III or IV gliomas who underwent FET-PET before surgical resection. Tumor overlap between FET-PET and CE was evaluated. Completeness of FET-PET resection (PET GTR) was calculated after superimposition and semi-automated segmentation of pre-operative FET-PET and postoperative MRI imaging. Survival analysis was performed using the Kaplan-Meier method and the log-rank test.
resultsFrom 30 included patients, PET GTR was achieved in 20 patients. Patients with PET GTR showed improved median OS with 19.3 compared to 13.7 months for patients with residual FET uptake (p = 0.007; HR 0.3; 95% CI 0.12-0.76). This finding remained as independent prognostic factor after performing multivariate analysis (HR 0.19, 95% CI 0.06-0.62, p = 0.006). Other survival influencing factors such as age, IDH-mutation, MGMT promotor status, and adjuvant treatment modalities were equally distributed between both groups.
conclusionOur results suggest that PET GTR improves the OS in patients with WHO grade III or IV gliomas. A multimodal imaging approach including FET-PET for surgical planning in newly diagnosed and recurrent tumors may improve the oncological outcome in glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.